Utama › Kanser Paru-paru Bukan Sel Kecil › California › Long Beach
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Long Beach, CA
12 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Long Beach (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Tibor Rubin VA Medical Center, Long Beach
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Mengambil pesertaFasa 3
- VA Long Beach Healthcare System ( Site 0199), Long Beach
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mengambil pesertaFasa 3
- MemorialCare Long Beach Medical Center, Long Beach
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Memorial Care Long Beach Medical Center, Long Beach
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- City of Hope Long Beach Elm, Long Beach
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mengambil pesertaFasa 3
- Helios Clinical Research, Long Beach
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mengambil pesertaFasa 2/3
- Local Institution - 007-898-B, Long Beach
- MemorialCare - Long Beach Medical Center, Long Beach
AOH1996 for the Treatment of Refractory Solid Tumors
Mengambil pesertaFasa 1
- City of Hope at Long Beach Elm, Long Beach
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Mengambil pesertaFasa 2
- City of Hope at Long Beach Elm, Long Beach
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Mengambil peserta
- VA Long Beach Healthcare System, Long Beach, CA, Long Beach
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Mengambil pesertaFasa 1/2
- VA Long Beach Healthcare System, Long Beach, CA, Long Beach
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Mengambil peserta
- VA Long Beach Healthcare System, Long Beach, CA, Long Beach
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Long Beach
- Diabetes Jenis 211 kajian
- Kanser Payudara9 kajian
- Kanser Paru-paru9 kajian
- Penyakit Alzheimer8 kajian
- Kanser Prostat7 kajian
- Penyakit Kardiovaskular6 kajian
- Kanser (semua jenis)6 kajian
- Obesiti5 kajian
- Berat Badan Berlebihan5 kajian
- Demensia5 kajian
- Penyakit Hati Steatotik4 kajian
- Limfoma Burkitt4 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.